핵심 개념
Despite progress in understanding and managing long COVID, the condition remains a significant challenge with persistent symptoms, limited treatment options, and a lack of urgency in research and development.
초록
The article provides a sobering look at the state of long COVID four years after the start of the COVID-19 pandemic. It highlights the following key points:
- Long COVID has emerged as a chronic disease with a wide range of debilitating symptoms, affecting 6.4% of Americans.
- While physicians have a better understanding of long COVID and have refined diagnostic tests, there is still no single diagnostic tool that works for all patients.
- Promising treatments have emerged, such as vagus nerve stimulation and the use of beta-blockers and low-dose naltrexone to manage specific symptoms like brain fog, fatigue, and rapid heart rate.
- Large clinical trials are underway, including efforts to repurpose HIV antivirals and investigate SARS-CoV-2 monoclonal antibodies as potential treatments.
- The NIH's RECOVER initiative has gathered a significant amount of data, but some experts feel the progress is too slow, and more urgency is needed to understand the disease mechanism, risk factors, and societal/economic implications.
- The chronic nature of long COVID, with some patients being ill for years, is a significant concern, as it can have a profound impact on patients' lives and the healthcare system.
통계
6.4% of Americans report symptoms of long COVID
A January 2021 study found very high levels of the neurotransmitter catecholamine as an indicator of long COVID
A 2022 study found lower serotonin levels in patients with long COVID
A March 2022 study showed that beta-blockers can help manage postural tachycardia syndrome, a symptom of long COVID
A January 2024 article found that low-dose naltrexone improved fatigue symptoms in long COVID patients
인용구
"It's still a moving target," said Nisha Viswanathan, MD, director of the University of California Los Angeles Long COVID Program at UCLA Health, meaning that the disease is always changing based on the variant of acute COVID.
"We did trials for COVID-19 vaccines at warp speed, but we're doing trials for long COVID at a snail's pace," said Ziyad Al-Aly, MD, a global expert on long COVID.